A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer

Por Kruczek, K, Ratterman, M, Tolzien, K, Sulo, S, Lestingi, T M, Nabhan, C
Publicado em 2013

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer

Por Nabhan, C, Villines, D, Valdez, T V, Tolzien, K, Lestingi, T M, Bitran, J D, Christner, S M, Egorin, M J, Beumer, J H
Publicado em 2012

A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma

Por Evens, A. M., Carson, K. R., Kolesar, J., Nabhan, C., Helenowski, I., Islam, N., Jovanovic, B., Barr, P. M., Caimi, P. F., Gregory, S. A., Gordon, L. I.
Publicado em 2013

A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma

Por Evens, A. M., Carson, K. R., Kolesar, J., Nabhan, C., Helenowski, I., Islam, N., Jovanovic, B., Barr, P. M., Caimi, P. F., Gregory, S. A., Gordon, L. I.
Publicado no Ann Oncol (2014)

Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy

Por Abramson, J. S., Feldman, T., Kroll-Desrosiers, A. R., Muffly, L. S., Winer, E., Flowers, C. R., Lansigan, F., Nabhan, C., Nastoupil, L. J., Nath, R., Goy, A., Castillo, J. J., Jagadeesh, D., Woda, B., Rosen, S. T., Smith, S. M., Evens, A. M.
Publicado no Ann Oncol (2014)